KR20040066088A - 응급피임용 투약방법 및 약제학적 조성물 - Google Patents
응급피임용 투약방법 및 약제학적 조성물 Download PDFInfo
- Publication number
- KR20040066088A KR20040066088A KR10-2004-7002069A KR20047002069A KR20040066088A KR 20040066088 A KR20040066088 A KR 20040066088A KR 20047002069 A KR20047002069 A KR 20047002069A KR 20040066088 A KR20040066088 A KR 20040066088A
- Authority
- KR
- South Korea
- Prior art keywords
- levonorgestrel
- active ingredient
- pharmaceutical composition
- emergency
- pharmaceutical
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 21
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims abstract description 45
- 229960004400 levonorgestrel Drugs 0.000 claims abstract description 45
- 230000001568 sexual effect Effects 0.000 claims abstract description 22
- 239000004480 active ingredient Substances 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000000654 additive Substances 0.000 claims abstract 5
- 239000003085 diluting agent Substances 0.000 claims abstract 5
- 239000000796 flavoring agent Substances 0.000 claims abstract 5
- 239000003205 fragrance Substances 0.000 claims abstract 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 5
- 235000019634 flavors Nutrition 0.000 claims abstract 4
- 239000003381 stabilizer Substances 0.000 claims abstract 4
- 230000002708 enhancing effect Effects 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 25
- 239000003433 contraceptive agent Substances 0.000 claims description 14
- 230000002254 contraceptive effect Effects 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims 6
- 230000000996 additive effect Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 239000003860 topical agent Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 3
- 239000003826 tablet Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 239000000843 powder Substances 0.000 description 8
- 230000035935 pregnancy Effects 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 230000016087 ovulation Effects 0.000 description 7
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 229960001021 lactose monohydrate Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 229940099112 cornstarch Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 229960002568 ethinylestradiol Drugs 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 3
- 210000003756 cervix mucus Anatomy 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940038565 levonorgestrel 1.5 mg Drugs 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 239000003539 oral contraceptive agent Substances 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940124558 contraceptive agent Drugs 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 239000008384 inner phase Substances 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 231100000544 menstrual irregularity Toxicity 0.000 description 2
- 239000008385 outer phase Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- ORKBYCQJWQBPFG-WOMZHKBXSA-N (8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 ORKBYCQJWQBPFG-WOMZHKBXSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 208000031271 Unwanted pregnancy Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000021962 pH elevation Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000019100 sperm motility Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (5)
- 활성성분으로서 레보노르게스트렐을 함유하는 응급피임용 약제학적 조성물에 있어서, 각 복용량내에 약제학적 분야에서 일반적으로 사용되는 제제화 증진 또는 제제화 제공 첨가제와 함께 공지된 부형제, 희석제, 향미제 또는 방향제, 안정화제와 혼합된 1.5 ± 0.2mg의 레보노르게스트렐만을 활성성분으로 함유하는 것을 특징으로 하는 응급피임용 약제학적 조성물.
- 활성성분으로서 레보노르게스트렐을 사용하는 응급피임용 투약방법에 있어서, 성행위의 72시간까지 활성성분으로 1.5 ± 0.2mg의 레보노르게스트렐을 함유하는 일회 투여 복용량을 투여하는 것을 특징으로 하는 응급피임용 투약방법.
- 활성성분으로서 레보노르게스트렐을 함유하는제 2항에 기재된 투약계획에 따라 사용된 응급피임용 약제학적 조성물에 있어서, 각 복용량내에 약제학적 분야에서 일반적으로 사용되는 제제화 증진 또는 제제화 제공 첨가제와 함께 공지된 부형제, 희석제, 향미제 또는 방향제, 안정화제와 혼합된 1.5 ± 0.2mg의 레보노르게스트렐만을 활성성분으로 함유하는 것을 특징으로 하는 응급피임용 약제학적 조성물.
- 응급피임용 일회 투여 복용량의 약제학적 조성물을 제조하기 위한 레보노르게스트렐의 용도에 있어서, 각 복용량내에 약제학적 분야에서 일반적으로 사용되는 제제화 증진 또는 제제화 제공 첨가제와 함께 공지된 부형제, 희석제, 향미제 또는 방향제, 안정화제와 혼합된 1.5 ± 0.2mg의 레보노르게스트렐만을 활성성분으로 함유하는 것을 특징으로 하는 레보노르게스트렐의 용도.
- 응급피임용 일회 투여 복용량의 약제학적 조성물의 제조방법에 있어서, 각 복용량내에 약제학적 분야에서 일반적으로 사용되는 제제화 증진 또는 제제화 제공 첨가제와 함께 공지된 부형제, 희석제, 향미제 또는 방향제, 안정화제와 혼합된 1.5 ± 0.2mg의 레보노르게스트렐만을 활성성분으로 함유하는 것을 특징으로 하는 응급피임용 약제학적 조성물의 제조방법.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0105173A HU227198B1 (en) | 2001-11-27 | 2001-11-27 | Pharmaceutical composition for emergency contraception containing levonorgestrel |
HUP0105173 | 2001-11-27 | ||
PCT/HU2002/000129 WO2003045397A1 (en) | 2001-11-27 | 2002-11-26 | Dosage regimen and pharmaceutical composition for emergency contraception |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040066088A true KR20040066088A (ko) | 2004-07-23 |
KR100908161B1 KR100908161B1 (ko) | 2009-07-16 |
Family
ID=89998939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047002069A KR100908161B1 (ko) | 2001-11-27 | 2002-11-26 | 응급피임용 투약방법 및 약제학적 조성물 |
Country Status (33)
Country | Link |
---|---|
US (1) | US20050288264A2 (ko) |
EP (1) | EP1448207B1 (ko) |
JP (1) | JP2005516904A (ko) |
KR (1) | KR100908161B1 (ko) |
CN (1) | CN1551774A (ko) |
AP (1) | AP1849A (ko) |
AT (1) | ATE293978T1 (ko) |
AU (1) | AU2002347401A1 (ko) |
BR (1) | BR0210595A (ko) |
CA (1) | CA2450359C (ko) |
DE (1) | DE60203929T2 (ko) |
DK (1) | DK1448207T3 (ko) |
EA (1) | EA006545B1 (ko) |
EC (1) | ECSP045171A (ko) |
ES (1) | ES2239727T3 (ko) |
GE (1) | GEP20063882B (ko) |
HR (1) | HRP20040584B1 (ko) |
HU (1) | HU227198B1 (ko) |
IL (1) | IL159394A0 (ko) |
IS (1) | IS2691B (ko) |
MA (1) | MA27076A1 (ko) |
MX (1) | MXPA04005104A (ko) |
NO (1) | NO333984B1 (ko) |
NZ (1) | NZ530056A (ko) |
OA (1) | OA12730A (ko) |
PL (1) | PL206010B1 (ko) |
PT (1) | PT1448207E (ko) |
RS (1) | RS50768B (ko) |
SI (1) | SI1448207T1 (ko) |
TN (1) | TNSN04048A1 (ko) |
UA (1) | UA79942C2 (ko) |
WO (1) | WO2003045397A1 (ko) |
ZA (1) | ZA200404114B (ko) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0719486A2 (pt) * | 2006-12-20 | 2014-02-18 | Duramed Pharmaceuticals Inc | "forma farmacêutica sólida oral desitegrante, não-efervescente, métodos para tratar uma mulher que necessite de um contraceptivo de emergência, pacote terapêutico para tratar uma mulher que necessite de contracepção de emergência e processo para a preparação de uma forma sólida de dosagem farmacêutica oral desintegrante, não-efervescente" |
JP2011507853A (ja) * | 2007-12-20 | 2011-03-10 | テバ ウィメンズ ヘルス インコーポレイテッド | 緊急避妊のための投与量レジメンならびに薬学的組成物およびパッケージ |
US8512745B2 (en) | 2008-12-08 | 2013-08-20 | Laboratoire Hra Pharma | Ulipristal acetate tablets |
US9180131B2 (en) | 2008-12-12 | 2015-11-10 | Laboratoire Hra Pharma | Method for contraception |
LT2419108T (lt) | 2009-04-14 | 2016-12-27 | Laboratoire Hra Pharma | Kontracepcijos pagal poreikį būdas |
MX2011013959A (es) | 2009-06-23 | 2012-01-25 | Bayer Pharma AG | Composicion farmaceutica para la anticoncepcion de emergencia. |
CN101732324B (zh) * | 2009-12-31 | 2011-12-07 | 广州朗圣药业有限公司 | 一种含有左炔诺孕酮的紧急避孕药物组合物及其制备方法 |
CA2835979C (en) | 2011-06-01 | 2018-05-01 | Estetra S.A. | Process for the production of estetrol intermediates |
PT2714710T (pt) | 2011-06-01 | 2016-07-12 | Estetra Sprl | Processo para a produção de intermediários de estetrol |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
WO2013021025A1 (en) * | 2011-08-11 | 2013-02-14 | Estetra S.A. | Use of estetrol as emergency contraceptive |
KR20150085512A (ko) | 2012-11-22 | 2015-07-23 | 바이엘 파마 악티엔게젤샤프트 | 필요시 피임을 위한 레보노르게스트렐 및 cox 억제제 함유 제약 조성물의 용도 및 적용 요법 |
AP2015008855A0 (en) | 2013-05-23 | 2015-11-30 | Bayer Pharma AG | Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception |
CN103877058A (zh) * | 2014-03-26 | 2014-06-25 | 邵娜 | 一种左炔诺孕酮片及其制备工艺 |
EP3310346B1 (en) | 2015-06-18 | 2021-03-24 | Estetra SPRL | Orodispersible tablet containing estetrol |
SI3310333T1 (sl) | 2015-06-18 | 2020-08-31 | Estetra Sprl | Orodisperzibilna enota odmerka, ki vsebuje komponento estetrola |
CA2988485A1 (en) | 2015-06-18 | 2016-12-22 | Mithra Pharmaceuticals S.A. | Orodispersible tablet containing estetrol |
KR102664563B1 (ko) | 2015-06-18 | 2024-05-09 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 에스테트롤 성분을 함유하는 구강분해성 투여 단위 |
CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
CN110917154A (zh) * | 2019-12-12 | 2020-03-27 | 上海信谊天平药业有限公司 | 一种左炔诺孕酮片的制备方法 |
WO2022026901A2 (en) * | 2020-07-30 | 2022-02-03 | Acer Therapeutics Inc. | Nk antagonists for contraception |
-
2001
- 2001-11-27 HU HU0105173A patent/HU227198B1/hu unknown
-
2002
- 2002-11-26 RS YUP-42/04A patent/RS50768B/sr unknown
- 2002-11-26 SI SI200230132T patent/SI1448207T1/xx unknown
- 2002-11-26 AU AU2002347401A patent/AU2002347401A1/en not_active Abandoned
- 2002-11-26 KR KR1020047002069A patent/KR100908161B1/ko active IP Right Grant
- 2002-11-26 GE GE5567A patent/GEP20063882B/en unknown
- 2002-11-26 CN CNA028137523A patent/CN1551774A/zh active Pending
- 2002-11-26 JP JP2003546899A patent/JP2005516904A/ja not_active Withdrawn
- 2002-11-26 OA OA1200400148A patent/OA12730A/fr unknown
- 2002-11-26 EA EA200400731A patent/EA006545B1/ru unknown
- 2002-11-26 NZ NZ530056A patent/NZ530056A/en not_active IP Right Cessation
- 2002-11-26 UA UA20040504015A patent/UA79942C2/uk unknown
- 2002-11-26 ES ES02783334T patent/ES2239727T3/es not_active Expired - Lifetime
- 2002-11-26 BR BR0210595-0A patent/BR0210595A/pt not_active Application Discontinuation
- 2002-11-26 WO PCT/HU2002/000129 patent/WO2003045397A1/en active IP Right Grant
- 2002-11-26 IL IL15939402A patent/IL159394A0/xx unknown
- 2002-11-26 AP APAP/P/2004/003046A patent/AP1849A/en active
- 2002-11-26 AT AT02783334T patent/ATE293978T1/de active
- 2002-11-26 DE DE60203929T patent/DE60203929T2/de not_active Expired - Lifetime
- 2002-11-26 PT PT02783334T patent/PT1448207E/pt unknown
- 2002-11-26 EP EP02783334A patent/EP1448207B1/en not_active Expired - Lifetime
- 2002-11-26 DK DK02783334T patent/DK1448207T3/da active
- 2002-11-26 MX MXPA04005104A patent/MXPA04005104A/es active IP Right Grant
- 2002-11-26 CA CA2450359A patent/CA2450359C/en not_active Expired - Lifetime
- 2002-11-26 PL PL369520A patent/PL206010B1/pl unknown
-
2003
- 2003-12-05 IS IS7065A patent/IS2691B/is unknown
-
2004
- 2004-03-26 TN TNP2004000048A patent/TNSN04048A1/en unknown
- 2004-04-20 NO NO20041607A patent/NO333984B1/no not_active IP Right Cessation
- 2004-04-21 MA MA27643A patent/MA27076A1/fr unknown
- 2004-05-26 ZA ZA2004/04114A patent/ZA200404114B/en unknown
- 2004-06-24 HR HR20040584 patent/HRP20040584B1/xx not_active IP Right Cessation
- 2004-06-25 EC EC2004005171A patent/ECSP045171A/es unknown
- 2004-10-05 US US10/495,923 patent/US20050288264A2/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100908161B1 (ko) | 응급피임용 투약방법 및 약제학적 조성물 | |
RU2542779C2 (ru) | Способ контрацепции, используемый по мере необходимости | |
JP5801801B2 (ja) | 緊急避妊のための医薬組成物及び処置方法 | |
KR102164693B1 (ko) | 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트 | |
JPH1129481A (ja) | 月経の出血を少なくし維持された効力を持つ超低投与量避妊薬 | |
JP2012502988A (ja) | 月経抑制、避妊、およびホルモン補充療法のための製剤、ならびにその投与方法 | |
JPH04273822A (ja) | 子宮内膜症の治療薬 | |
US4639439A (en) | Contraceptive composition | |
JP2001523639A (ja) | プロゲストゲン−抗プロゲストゲンレジメン | |
WO2010007629A1 (en) | A kit comprising anti-emetic and oral contraceptive | |
KR102210982B1 (ko) | 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트 | |
CN117715644A (zh) | 纯孕激素口服避孕 | |
JP2007197459A (ja) | 月経の出血を少なくし維持された効力を持つ超低投与量避妊薬 | |
KR20010110807A (ko) | 조합 치료에서의 항프로게스타겐의 용도 | |
SK122897A3 (en) | Application of 8,9-dehydroestrone as an estrogen with neutral effect on the prolactin level |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130509 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140521 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20150430 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160511 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20180525 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20190530 Year of fee payment: 11 |